On Friday, H.C. Wainwright maintained its Buy rating on Vigil Neuroscience Inc (NASDAQ: VIGL), underlining the company's potential in the biotechnology sector. The endorsement comes after Adagene, which presented at the 2nd Annual Immune Cell Engager Conference on June 25, revealed significant preclinical results for its T cell engager (TCE) programs.
The conference featured a conversation with Dr. Peter Luo, Chairman, CEO, and Co-Founder of Adagene, who discussed the company's innovative TCE programs, ADG138 and ADG152. These molecules have shown promising results in preclinical studies, exhibiting anti-tumor activity in mice, along with favorable pharmacokinetics and safety profiles in non-human primates. ADG138, in particular, demonstrated notable efficacy in a tumor model that was non-responsive to other treatments, while inducing significantly lower levels of the inflammatory cytokine IL-6.
The data presented underscore Adagene's proprietary SAFEbody platform's ability to develop effective TCEs. Dr. Luo noted that both ADG138 and ADG152 possess a robust CMC process, akin to that of typical monoclonal antibodies, with stable constructs that are simple to purify and formulate.
Despite these advancements, Adagene has indicated that due to resource limitations, it will not progress these two TCE programs into clinical development. Instead, the company's strategy is to concentrate on advancing its CTLA-4 and CD137 programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.